









市場行情
/
股票
/
nasdaq-krys
/

Krystal Biotech Inc

KRYS

240.800USD

+7.430+3.18%

收盤 12/19, 16:00（美東）報價延遲15分鐘

6.98B總市值

34.91本益比TTM



Krystal Biotech Inc

240.800

+7.430+3.18%

概覽公司財務分析

概覽

公司

財務

分析

關於 Krystal Biotech Inc 公司

Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.

Krystal Biotech Inc簡介



公司代碼KRYS

公司名稱Krystal Biotech Inc

上市日期Sep 20, 2017

CEOKrishnan (Krish S)

員工數量275

證券類型Ordinary Share

年結日Sep 20

公司地址2100 Wharton St Ste 701

城市PITTSBURGH

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編15203

電話14125865830

網址https://www.krystalbio.com/

公司代碼KRYS

上市日期Sep 20, 2017

CEOKrishnan (Krish S)

Krystal Biotech Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Krish S. Krishnan

Chairman of the Board, President, Chief Executive Officer

1.62M

-1.82%

Ms. Suma M. Krishnan

President - Research and Development, Founder, Director

1.55M

-1.58%

Mr. Dino A. Rossi

Independent Director

78.69K

Dr. Adm. Christopher (Chris) Mason, M.D., Ph.D.

Independent Director

Mr. Kirti Ganorkar

Independent Director

Mr. Daniel S. Janney

Lead Independent Director

Ms. Catherine Mazzacco

Independent Director

Dr. Everett Rand Sutherland, M.D.

Independent Director

Mr. Julian S. Gangolli

Independent Director

Ms. Meg Dodge

Investor Relations

名稱

名稱/職務

職務

持股

持股變動

Mr. Krish S. Krishnan

Chairman of the Board, President, Chief Executive Officer

1.62M

-1.82%

Ms. Suma M. Krishnan

President - Research and Development, Founder, Director

1.55M

-1.58%

Mr. Dino A. Rossi

Independent Director

78.69K

Dr. Adm. Christopher (Chris) Mason, M.D., Ph.D.

Independent Director

Mr. Kirti Ganorkar

Independent Director

Mr. Daniel S. Janney

Lead Independent Director

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月21日週五

持股股東

股東類型

持股股東

佔比

Fidelity Management & Research Company LLC

14.95%

BlackRock Institutional Trust Company, N.A.

12.07%

The Vanguard Group, Inc.

9.61%

Avoro Capital Advisors LLC

9.58%

Krishnan (Krish S)

5.58%

其他

48.21%

持股股東

佔比

Fidelity Management & Research Company LLC

14.95%

BlackRock Institutional Trust Company, N.A.

12.07%

The Vanguard Group, Inc.

9.61%

Avoro Capital Advisors LLC

9.58%

Krishnan (Krish S)

5.58%

其他

48.21%

股東類型

持股股東

佔比

Investment Advisor

53.56%

Investment Advisor/Hedge Fund

29.28%

Individual Investor

11.65%

Hedge Fund

8.97%

Private Equity

2.85%

Research Firm

1.95%

Pension Fund

1.09%

Sovereign Wealth Fund

1.00%

Bank and Trust

0.44%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

611

28.05M

96.74%

-1.59M

2025Q2

590

32.63M

112.75%

-1.09M

2025Q1

597

32.73M

113.26%

-1.18M

2024Q4

555

33.11M

114.98%

-1.88M

2024Q3

532

33.56M

116.82%

-1.97M

2024Q2

492

34.00M

119.08%

+2.68M

2024Q1

457

29.99M

105.21%

-815.24K

2023Q4

418

29.64M

105.24%

-696.04K

2023Q3

406

29.89M

107.26%

-297.23K

2023Q2

399

29.15M

106.30%

+625.16K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Fidelity Management & Research Company LLC

4.33M

14.95%

+13.93K

+0.32%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

3.52M

12.16%

-115.65K

-3.18%

Jun 30, 2025

The Vanguard Group, Inc.

2.82M

9.74%

-2.39K

-0.08%

Jun 30, 2025

Avoro Capital Advisors LLC

2.66M

9.19%

-71.00K

-2.60%

Jun 30, 2025

Krishnan (Krish S)

1.65M

5.69%

-25.00K

-1.49%

Jul 16, 2025

Krishnan (Suma M)

1.58M

5.45%

-25.00K

-1.56%

Jul 16, 2025

State Street Investment Management (US)

1.36M

4.68%

+128.64K

+10.49%

Jun 30, 2025

Soleus Capital Management, L.P.

922.96K

3.19%

+481.20K

+108.93%

Jun 30, 2025

Capital World Investors

942.25K

3.26%

-12.22K

-1.28%

Jun 30, 2025

Frazier Life Sciences Management, L.P.

688.46K

2.38%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Franklin Genomic Advancements ETF

5.26%

First Trust NYSE Arca Biotechnology Index Fund

3.66%

Invesco S&P SmallCap Health Care ETF

3.12%

Clough Hedged Equity ETF

2.47%

Invesco S&P SmallCap 600 GARP ETF

2.31%

ALPS Medical Breakthroughs ETF

2.28%

Virtus LifeSci Biotech Products ETF

2.25%

State Street SPDR S&P Biotech ETF

2.07%

Invesco S&P SmallCap 600 Pure Growth ETF

1.54%

WisdomTree BioRevolution Fund

1.35%

Franklin Genomic Advancements ETF

佔比5.26%

First Trust NYSE Arca Biotechnology Index Fund

佔比3.66%

Invesco S&P SmallCap Health Care ETF

佔比3.12%

Clough Hedged Equity ETF

佔比2.47%

Invesco S&P SmallCap 600 GARP ETF

佔比2.31%

ALPS Medical Breakthroughs ETF

佔比2.28%

Virtus LifeSci Biotech Products ETF

佔比2.25%

State Street SPDR S&P Biotech ETF

佔比2.07%

Invesco S&P SmallCap 600 Pure Growth ETF

佔比1.54%

WisdomTree BioRevolution Fund

佔比1.35%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Krystal Biotech Inc的前五大股東是誰？



Krystal Biotech Inc的前五大股東如下：
Fidelity Management & Research Company LLC
持有股份：4.33M
佔總股份比例：14.95%。
BlackRock Institutional Trust Company, N.A.
持有股份：3.52M
佔總股份比例：12.16%。
The Vanguard Group, Inc.
持有股份：2.82M
佔總股份比例：9.74%。
Avoro Capital Advisors LLC
持有股份：2.66M
佔總股份比例：9.19%。
Krishnan (Krish S)
持有股份：1.65M
佔總股份比例：5.69%。